Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway

Huang,Li; Kong,Yong; Wang,Jing; Sun,Jie; Shi,Qin; Qiu,Yu‑Hua

doi:10.3892/mmr.2015.3953

Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway

Authors:
- Li Huang
- Yong Kong
- Jing Wang
- Jie Sun
- Qin Shi
- Yu‑Hua Qiu
View Affiliations

Affiliations: Department of Internal Medicine, Children's Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China, Department of Immunology, Medical College, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Laboratory Animal Center of Soochow University, Suzhou, Jiangsu 215123, P.R. China, Division of Nano Biomedicine, Suzhou Institute of Nano‑Tech and Nano‑Bionics, Chinese Academy of Sciences, Suzhou, Jiangsu 215000, P.R. China, Department of Orthopedics, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215123, P.R. China
Published online on: June 18, 2015 https://doi.org/10.3892/mmr.2015.3953
Pages: 4187-4195
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate the effects of the B7/cluster of differentiation (CD)28 signaling pathway on experimental lupus nephritis and examine the molecular mechanism involved by inhibiting the B7/CD28 signaling pathway. A lupus nephritis model in C57BL/6 J mice was induced via intraperitoneal injection of pristane. A recombinant B7‑1 short hairpin RNA (shRNA) lentivirus vector was constructed by synthesis and splicing. A neutralizing mouse anti‑human B7‑1 antibody termed 4E5 was also prepared. The mouse model of lupus nephritis was treated with B7‑1 shRNA and 4E5 via injection through the tail vein. The silencing effects of B7‑1 shRNA lentiviral infection on target molecules were evaluated using immunofluorescence and flow cytometry. The levels of protein in the urine were detected using Albustix test paper each month over 10 months. The concentration of interleukin (IL)‑4 and interferon‑γ in the serum was determined using an ELISA. The immune complex (IC) deposits in the kidney were analyzed using direct immunofluorescence. The results demonstrated that the C57BL/6 J mouse lupus nephritis model was successfully constructed with immune cells activated in the spleen of the mice, increases in the concentration of anti‑nuclear antibody (ANA) and anti‑double stranded DNA antibodies as well as positive IC formation. Following B7‑1 shRNA lentivirus or 4E5 treatment, CD11b+B7‑1+, CD11c+B7‑1+ and CD21+B7‑1+ cells in the spleen of the mice were significantly reduced. The concentration of ANA and IL‑4 in the serum was also decreased. The concentration of urine protein was reduced and it was at its lowest level in the 4E5 early intervention group. It was also revealed that the immunofluorescence intensity of the IC deposits was weak in the 4E5 early intervention group. In conclusion, inhibiting the B7‑1/CD28 signaling pathway is able to alleviate experimental lupus nephritis and provides an experimental basis for the therapeutic use of blocking the B7‑1/CD28 signaling pathway in human lupus nephritis and other autoimmune disorders.

View Figures

View References

1	Tenbrock K, Juang YT, Kyttaris VC and Tsokos GC: Altered signal transduction in SLE T cells. Rheumatology (Oxford). 46. pp. 1525–1530. 2007, View Article : Google Scholar
2	Ohl K and Tenbrock K: Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2011:4325952011. View Article : Google Scholar : PubMed/NCBI
3	Kinoshita K, Kishimoto K, Shimazu H, et al: Successful treatment with retinoids in patients with lupus nephritis. Am J Kidney Dis. 55:344–347. 2010. View Article : Google Scholar
4	Saxena R, Mahajan T and Mohan C: Lupus nephritis: current update. Arthritis Res Ther. 13:2402011. View Article : Google Scholar : PubMed/NCBI
5	Bertsias G, Gordon C and Boumpas DT: Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. Lupus. 17:437–442. 2008. View Article : Google Scholar : PubMed/NCBI
6	Thompson CB: Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell. 81:979–982. 1995. View Article : Google Scholar : PubMed/NCBI
7	King CL, Xianli J, June CH, Abe R and Lee KP: CD28-deficient mice generate an impaired Th2 response to Schistosoma mansoni infection. Eur J Immunol. 26:2448–2455. 1996. View Article : Google Scholar : PubMed/NCBI
8	Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:3245–3287. 1997.PubMed/NCBI
9	Nossal GJ: Negative selection of lymphocytes. Cell. 76:229–239. 1994. View Article : Google Scholar : PubMed/NCBI
10	Dong GC, Chuang PH, Chang KC, et al: Blocking effect of an immuno-suppressive agent, cynarin, on CD28 of T-cell receptor. Pharm Res. 26:375–381. 2009. View Article : Google Scholar :
11	Fire A: RNA-triggered gene silencing. Trends Genet. 15:358–363. 1999. View Article : Google Scholar : PubMed/NCBI
12	Yelton DE and Scharff MD: Monoclonal antibodies: a powerful new tool in biology and medicine. Annu Rev Biochem. 50:657–680. 1981. View Article : Google Scholar : PubMed/NCBI
13	McCoy KD and Le Gros G: The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol. 77:1–10. 1999. View Article : Google Scholar : PubMed/NCBI
14	Shi Q, Gao ZY, Xie F, Wang LF, Gu YP, Yang TJ, Huang L, Qian QH and Qiu YH: A novel monoclonal antibody against human CD80 and its immune protection in a mouse lupus-like disease. Int J Immunopathol Pharmacol. 24:583–593. 2011.PubMed/NCBI
15	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
16	Satoh M and Reeves WH: Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med. 180:2341–2346. 1994. View Article : Google Scholar : PubMed/NCBI
17	Richards HB, Satoh M, Jennette JC, Croker BP, Yoshida H and Reeves WH: Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int. 60:2173–2180. 2001. View Article : Google Scholar : PubMed/NCBI
18	Dias N and Stein CA: Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther. 1:347–355. 2002.PubMed/NCBI
19	Zang X and Allison JP: The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res. 13:5271–5279. 2007. View Article : Google Scholar : PubMed/NCBI
20	Howard LM, Kohm AP, Castaneda CL and Miller SD: Therapeutic blockade of TCR signal transduction and co-stimulation in autoimmune disease. Curr Drug Targets Inflamm Allergy. 4:205–216. 2005. View Article : Google Scholar : PubMed/NCBI
21	Kremer JM, Genant HK, Moreland LW, et al: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 144:865–876. 2006. View Article : Google Scholar : PubMed/NCBI
22	Miyagishi M, Hayashi M and Taira K: Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13:1–7. 2003. View Article : Google Scholar : PubMed/NCBI
23	Nakajima A, Azuma M, Kodera S, et al: Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule. Eur J Immunol. 25:3060–3069. 1995. View Article : Google Scholar : PubMed/NCBI
24	Cunnane G, Chan OT, Cassafer G, et al: Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum. 50:1539–1548. 2004. View Article : Google Scholar : PubMed/NCBI
25	Kubowicz P, Żelaszczyk D and Pękala E: RNAi in clinical studies. Curr Med Chem. 20:1801–1816. 2013. View Article : Google Scholar : PubMed/NCBI
26	Talaat RM, Mohamed SF, Bassyouni IH and Raouf AA: Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine. 72:146–153. 2015. View Article : Google Scholar : PubMed/NCBI
27	Dolff S, Bijl M, Huitema MG, Limburg PC, Kallenberg CG and Abdulahad WH: Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus. Clin Immunol. 141:197–204. 2011. View Article : Google Scholar : PubMed/NCBI
28	Lazarus M, Hajeer AH, Turner D, et al: Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol. 24:2314–2317. 1997.
29	Hasegawa K, Hayashi T and Maeda K: Promotion of lupus in NZB x NZWF1 mice by plasmids encoding interferon (IFN)-gamma but not by those encoding interleukin (IL)-4. J Comp Pathol. 127:1–6. 2002. View Article : Google Scholar : PubMed/NCBI
30	Amel-Kashipaz MR, Huggins ML, Lanyon P, Robins A, Todd I and Powell RJ: Quantitative and qualitative analysis of the balance between type 1 and type 2 cytokine-producing CD8 (−) and CD8(+) T cells in systemic lupus erythematosus. J Autoimmun. 17:155–163. 2001. View Article : Google Scholar : PubMed/NCBI
31	Solomou EE, Juang YT, Gourley MF, Kammer GM and Tsokos GC: Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol. 166:4216–4222. 2001. View Article : Google Scholar : PubMed/NCBI
32	Szegedi A, Simics E, Aleksza M, et al: Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus. Rheumatology (Oxford). 44. pp. 925–931. 2005, View Article : Google Scholar
33	Svoboda P: Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr Opin Mol Ther. 9:248–257. 2007.PubMed/NCBI
34	Zhang JL, Sun DJ, Hou CM, et al: CD3 mAb treatment ameliorated the severity of the cGVHD-induced lupus nephritis in mice by up-regulation of Foxp3+ regulatory T cells in the target tissue: kidney. Transpl Immunol. 24:17–25. 2010. View Article : Google Scholar : PubMed/NCBI